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Abstract
Introduction
In light of the limited impact the syndromic management approach has had on the global
sexually transmitted infection (STI) epidemic, we assessed a care model comprising point-
of-care (POC) STI testing, immediate treatment, and expedited partner therapy (EPT)
among a cohort of young women at high HIV risk in South Africa.
Methods and findings
HIV negative women presenting for STI care underwent POC testing for Chlamydia tracho-
matis (CT), Neisseria gonorrhoeae (NG) and Trichomonas vaginalis (TV), and swabs were
sent for NG culture and susceptibility testing. Results were available within 2 hours and
women with STIs were immediately treated and offered EPT packs, including medication,
condoms, and information for sexual partners. An EPT questionnaire was administered after
one week, and women retested for STIs after 6 and 12 weeks. 267 women, median age 23
(IQR 21–26), were recruited and 88.4% (236/267) reported genital symptoms. STI preva-
lence was CT 18.4% (95%CI 13.7–23.0), NG 5.2% (95%CI 2.6–7.9) and TV 3.0% (95%CI
1.0–5.0). After 12 weeks, all but one NG and two CT infections were cleared. No cephalospo-
rin-resistant NG was detected. Of 63/267 women (23.6%) diagnosed with STIs, 98.4% (62/
63) were offered and 87.1% (54/62) accepted EPT. At one week 88.9% (48/54) stated that
their partner had taken the medication. No allergic reactions or social harms were reported.
Of 51 women completing 6-week follow up, detection rates were lower amongst women
receiving EPT (2.2%, 1/46) compared to those who did not (40.0%, 2/5), p = 0.023. During
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focus group discussions women supported the care model, because they received a rapid,
specific diagnosis, and could facilitate their partners’ treatment.
Conclusions
POC STI testing and EPT were acceptable to young South African women and their part-
ners, and could play an important role in reducing STI reinfection rates and HIV risk. Larger
studies should evaluate the feasibility and cost-effectiveness of implementing this strategy
at population level.
Introduction
More than three decades into the HIV epidemic, little progress has been made in preventing
HIV acquisitions among young women in Sub-Saharan Africa [1]. Other sexually transmitted
infections (STIs) have long been recognized as major modifiable risk factors for HIV infection
[2,3,4,5,6], but effective STI care still does not reach the most vulnerable, especially in low- and
middle-income countries (LMICs) with high HIV burden. In addition, there are several major
complications of STIs including pelvic inflammatory disease with resultant tubal infertility,
risk of ectopic pregnancy and chronic pelvic pain; cervical and other genital tract tumours,
spread to the new born baby and psychosexual problems as well as a substantial economic bur-
den [7,8,9].
Despite the major health burden of STIs, governments in many LMICs have persisted with
the model of syndromic management, mainly because of limited resources, the lack of ade-
quate laboratory services, and to deliver immediate care by nurses [10,11,12]. The limitations
of this approach have been well documented and include the inability to detect asymptomatic
STIs [12,13,14], the poor positive predictive value of syndromic treatment resulting in the
overuse of antibiotics (of particular concern in relation to antibiotic resistance to gonorrhoea)
[15], the lack of antimicrobial susceptibility testing, and limited opportunities for routine sur-
veillance. In South Africa, syndromic management was implemented in 1995, and the preva-
lence of STIs remains unchanged [12,16,17]. Innovative, low-cost diagnostic models for
enhanced STI care are urgently required.
Another reason for poor outcomes with syndromic management is that there are limited
opportunities to find and treat sexual partners with appropriate medication. Diagnostic ser-
vices would allow for a specific diagnosis and appropriate treatment for the index case as well
as their partners. Several studies have shown that expedited partner therapy (EPT) for bacterial
STIs delivered by the index case or through pharmacies can reduce reinfection rates among
women [18,19]. While EPT has been implemented in some settings in the United States, only a
few studies from LMICs have suggested that EPT may be effective at increasing partner treat-
ment and reducing reinfection rates [20,21]. In South Africa, partner-delivered patient referral
remains the mainstay of contact tracing, but has been largely unsuccessful with partner treat-
ment rates below 22% [22].
The lack of data on the acceptability, feasibility and effectiveness of EPT in LMICs with
high HIV incidence settings is a major gap. If effective, this intervention could contribute to
the reduction of high STI rates among young women, by increasing partner treatment, thereby
lowering reinfection rates, and by potentially addressing other contributing factors including
stigma and the lack of knowledge about STIs [20]. This in turn could lead to a reduction in
HIV acquisition. The current interest in more affordable STI diagnostics, including point-of-
STI care model for LMICs
PLOS ONE | https://doi.org/10.1371/journal.pone.0196209 April 24, 2018 2 / 13
decision to publish, or preparation of the
manuscript.
Competing interests: The authors of this
manuscript have the following competing interests:
Cepheid Inc loaned two 4-module GeneXpert
machines to the study team free-of-charge, but had
no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript. This does not alter our adherence to
PLOS ONE policies on sharing data and materials.
care (POC) assays, could accelerate the introduction of EPT, as countries consider a shift from
syndromic to diagnostic management.
The objective of this study was to evaluate a POC diagnostic STI model combined with an
EPT intervention among young women at high HIV risk in South Africa.
Methods
Study design
This prospective cohort pilot study (CAPRISA 083) evaluated an enhanced STI management
intervention including POC STI testing, immediate supervised treatment, and EPT among
young women in South Africa. Women who consented were screened for STIs and bacterial
vaginosis (BV). Those with a STI and/or BV were treated and then booked to retest at the clinic
after 6 and 12 weeks.
Study setting
The CAPRISA 083 study was conducted in the Prince Cyril Zulu Communicable Disease Cen-
tre (PCZCDC), a large public healthcare clinic in the city centre of Durban, KwaZulu-Natal,
South Africa between May 2016 and January 2017. KwaZulu-Natal has one of the highest HIV
incidence rates among young women globally (up to 9%) [23]. The clinic provides general pri-
mary health care services for adults free of charge, focuses on the diagnosis and treatment of
HIV and Tuberculosis, and offers syndromic management for STIs in line with the South Afri-
can Department of Health guidelines [24].
Study population
Women attending the clinic for STI care were recruited and, if willing to participate, provided
written informed consent for the diagnostic care intervention instead of standard syndromic
management. Eligible patients were female, age 18–40 years, who had an HIV negative anti-
body test. As this was a proof-of-concept study, HIV positive or pregnant women, and sex
workers were excluded, because they either required specialized care, or were not the ideal tar-
get population for the EPT intervention due to multiple unknown clients. Ethical approval was
granted by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal
(BFC410/15), and the eThekwini Municipality gave permission to conduct the study at the
PCZCDC. Considering participants were offered a diagnostic intervention outside standard
care in South Africa, the study was registered online at www.clinicaltrials.gov under study
number NCT03407586.
Clinical assessment and sample collection
In order to streamline study visits, once a participant was enrolled, a professional nurse ini-
tially collected two blind vaginal swabs for STI testing and microscopy. While the testing was
underway in the clinic laboratory, the nurse continued with study procedures. First, she
administered a structured sexual behavioural questionnaire, which included questions on the
reasons for attending the clinic, recent sexual activity, number of partners, condom and con-
traceptive use, and pregnancy desire. The nurse then performed a general physical examina-
tion, followed by a pelvic examination with a speculum to assess for vulval, vaginal and
cervical abnormalities and to take additional study specimens including an Eswab™ to enable
bacterial culture and antimicrobial susceptibility testing.
STI care model for LMICs
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POC STI and antimicrobial susceptibility testing
All POC STI tests were conducted by laboratory technologists with experience with the Gen-
eXpert1 platform at the onsite laboratory and were processed within approximately 2 hours.
POC tests included the Xpert1 CT/NG assay (Cepheid, Sunnydale, California, US) to test for
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), the OSOM1 Rapid Trichomo-
nas Test (Sekisui Diagnostics, Lexington, MA, US) to detect Trichomonas vaginalis (TV), and
Gram stain microscopy to assess for candidiasis and BV by Nugent Score. Any cases of NG
were further investigated for culture and antimicrobial susceptibility at the Inkosi Albert
Luthuli National Health Laboratory Services reference laboratory using the collected Eswab™.
Immediate single dose treatment
Women diagnosed with CT, NG or TV were offered immediate supervised treatment with sin-
gle doses of antibiotics on the same visit. STI treatment was organism-specific following inter-
national guidelines, and was also compatible with national guidelines: Ceftriaxone 250mg
intramuscular and Azithromycin 1g oral for NG, Azithromycin 1g oral for CT, and Metroni-
dazole 2g oral for TV [24,25]. Women diagnosed with intermediate flora or BV (Nugent
Scores 4–6 and 7–10, respectively) were offered a single dose of oral Metronidazole 2g, and
those with candidiasis were treated with one Clotrimazole pessary and Clotrimazole cream, if
vulval symptoms were present.
Expedited partner therapy
Once treated for NG, CT or TV, women were offered EPT packs, which included appropriate
medication, male condoms and an information leaflet (S1 Fig) for the current partner/s. Part-
ner medication was equivalent to that received by the index case, except that NG was treated
with a single dose of oral Cefixime 400mg, instead of single dose intramuscular Ceftriaxone
250mg. The information leaflet was available in English or isiZulu, the local language, and con-
tained information on STIs, medication administration, potential side effects, and a contact
phone number, that the partner could call, if required. One week after their visit, women were
contacted by phone to administer an EPT questionnaire, and were then retested for STIs in the
clinic after 6 and 12 weeks.
Focus group discussions on POC testing and EPT
Women diagnosed with a STI were invited to take part in focus group discussions to learn
more about their experiences with the POC STI testing model and the feasibility and accept-
ability of EPT. Participants provided separate written informed consent and then joined one
of six sessions attended by 4 to 6 participants, which were conducted by one trained female
nurse psychologist and a female assistant. Women were encouraged to share their experiences
with disclosing the STI diagnosis to their partners and handing over the EPT pack. The nurse
then specifically enquired about potential social harms, including intimate partner violence.
Data analysis
Study data were collected and managed using REDCap electronic data capture tools (Vander-
bilt University, Nashville, TN, US), checked for internal validity and analyzed using SAS ver-
sion 9.4 (SAS Institute Inc., Cary, NC, USA). Baseline characteristics of the study participants
were summarized using descriptive statistics expressed as means with standard deviation or
medians with interquartile ranges (IQR) for continuous variables and proportions for categor-
ical variables. An independent samples t-test was used to compare two means of continuous
STI care model for LMICs
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variables, while the Wilcoxon-Mann-Whitney test was used to compare two medians. Propor-
tions were compared using Fisher’s exact test. Confidence intervals were calculated using the
Wald interval. A generalized estimating equation (GEE) model using a binomial distribution
and accounting for repeated measures was used to determine the effect of time on each STI.
All focus group discussions were digitally recorded, transcribed and translated into English,
and data were analysed thematically, using an open coding structure.
Results
Characteristics of study population
A total of 267 HIV negative women, median age 23 years (IQR 21–26), were enrolled into the
study. HIV positive women (screening prevalence 39.1%) and pregnant women (9.1%) were
excluded. Almost all women (99.6%, 262/263) had completed at least some secondary educa-
tion, and most (88.4%, 236/267) presented to the clinic because of STI symptoms (Table 1). All
women were sexually active and the majority reported only one male partner during the past 2
months, with the younger women (<25 year olds vs25 year olds) having slightly more sexual
partners in the past 12 months (p = 0.023).
Overall, 68.2% (182/267) of women stated that they used condoms with their partners,
although only 3.7% (10/267) used them consistently. One third of women (34.1%, 91/267)
used contraception (29.9% of<25 year olds), while two thirds (68.2%, 182/267), and especially
the younger women (75.7% vs 53.3%, p =<0.001), were concerned about an unplanned preg-
nancy. Almost half the women (46.8%, 124/267) had at least one abnormality on genital exami-
nation, including 84.7% (105/124) with vaginal discharge, 21.0% (26/124) with vulval signs
(warts, vulvitis, rash or vesicles) and 9.7% (12/124) with cervical abnormalities (warts, dis-
charge or inflammation).
STI and BV prevalence and antimicrobial susceptibility
Of the 267 women, 23.6% [95% Confidence interval (CI) 18.5–28.7%] were diagnosed with at
least one of the three STIs (Table 2). The overall prevalence of CT was 18.4% (95%CI 13.7–
23.0), and was 20.3% (95%CI 14.4–26.3) among women less than 25 years old. The prevalence
of NG was 5.2% (95%CI 2.6–7.9) and of TV 3.0% (95%CI 1.0–5.0). Seven women were diag-
nosed with both CT and NG, and one woman had both CT and TV infections. Two thirds of
women (69.3%, 185/267) had evidence of abnormal vaginal flora (33.7% BV and 35.6% inter-
mediate flora) based on Nugent Score, and 18.0% (48/267) were diagnosed with candidiasis. A
total of 19.5% (52/267) reported symptoms, but had no STI, abnormal flora or candidiasis on
laboratory examination. Of the 14 women diagnosed with NG on Xpert1 CT/NG, 64.3% (9/
14) grew NG on culture. 77.7% (7/9) were resistant to penicillin and 44.4% (4/9) to ciprofloxa-
cin, but no cephalosporin resistance was identified.
EPT uptake among women and their partners
Of the 63 women with a STI, 98.4% (62/63) were offered and 87.1% (54/62) accepted EPT for
their regular partner (Fig 1). The majority (85.7%, 54/63) of women had one partner in the
previous two months. Two women chose EPT for one additional casual partner. At telephonic
follow-up one week later, 88.9% (48/54) stated that they had successfully delivered EPT, i.e. the
partner ingested the medication either observed (77.8%, 42/54) or unobserved (11.1%, 6/54).
Five women (9.3%, 5/54) still had to deliver EPT, but managed to deliver it by the 6-week fol-
low-up visit, and one partner refused (1.8%, 1/54). Some women reported that they (16.7%, 9/
54) or their partners (6.3%, 3/46) experienced minor medication side effects consistent with
STI care model for LMICs
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the antibiotic profiles, but no allergic reactions or social harms including intimate partner vio-
lence were reported. Of the 82.3% (51/62) women completing 6-week follow up, detection
rates for any of the three STIs were lower amongst women receiving EPT (2.2%, 1/46), com-
pared to those not receiving EPT (40.0%, 2/5), p = 0.023 (Table 3).
STI detection rates after 6 and 12 weeks
Overall, 37.8% (101/267) women diagnosed with STIs or BV were scheduled for the 6 and
12-week follow-up visits. Retention was 83.2% (84/101) at both 6 and 12 weeks of follow-up
with 76.2% (77/101) attending all three clinic visits for retesting (Table 4). In a GEE analysis
modelling the effect of time, CT, NG and TV all decreased significantly from baseline with
only two cases of CT and one case of NG detected after 12 weeks. Women with BV often
Table 1. Characteristics of 267 young women attending STI care.
Variable Category Overall
(N = 267)
% (n/N)
< 25 years
(N = 177)
% (n/N)
 25 years
(N = 90)
% (n/N)
p-value
Age Median (IQR) 23 (21–26)
Highest level of education Primary 0.4 (1/263) 0 1.1 (1/89) 0.457
Secondary 73.0 (192/263) 73.6 (128/174) 71.9 (64/89)
Tertiary 26.6 (70/263) 26.4 (46/174) 27.0 (24/89)
Reason for presentation STI Symptoms 88.4 (236/267) 88.1 (156/177) 88.9 (80/90) 0.976
Asymptomatic check-up 7.9 (21/267) 7.9 (14/177) 7.8 (7/90)
Partner contact slip 0.7 (2/267) 1.1 (2/177) 0
Othera 3.0 (8/267) 2.8 (5/177) 3.3 (3/90)
Number of sex partners past 2 months Median (IQR) 1 (1–1) 1 (1–1) 1 (1–1) 0.257
Number of sex partners past 12 months Median (IQR) 1 (1–2) 1 (1–2) 1 (1–1) 0.023
Gender of sex partner/s Men 98.5 (263/267) 97.7 (173/177) 100 (90/90) 0.304
Men and women 1.5 (4/267) 2.3 (4/177) 0
Type of sexb Vaginal 100 (267/267) 100 (177/177) 100 (90/90) -
Oral 28.5 (76/267) 29.4 (52/177) 26.7 (24/90) 0.670
Anal 4.9 (13/267) 4.5 (8/177) 5.6 (5/90) 0.767
Any condom use with partner(s) Yes 68.2 (182/267) 73.4 (130/177) 57.8 (52/90) 0.012
Frequency of condom use Always 3.7 (10/267) 2.8 (5/177) 5.6 (5/90) 0.011
Sometimes 64.4 (172/267) 70.6 (125/177) 52.2 (47/90)
Never 31.8 (85/267) 26.6 (47/177) 42.2 (38/90)
Contraception use Yes 34.1 (91/267) 29.9 (53/177) 42.2 (38/90) 0.056
Progesterone injectionsc 59.3 (54/91) 58.5 (31/53) 60.5 (23/38) 0.913
Subdermal Implantd 19.8 (18/91) 22.6 (12/53) 15.8 (6/38)
Oral contraceptive pills 11.0 (10/91) 9.4 (5/53) 13.2 (5/38)
Condom only 7.7 (7/91) 7.5 (4/53) 7.9 (3/38)
Intra-uterine device 2.2 (2/91) 1.9 (1/53) 2.6 (1/38)
Currently trying to conceive a child Yes 10.5 (28/267) 6.8 (12/177) 17.8 (16/90) 0.010
Concerned about unplanned pregnancy Yes 68.2 (182/267) 75.7 (134/177) 53.3 (48/90) <0.001
Genital examination Abnormal 46.4 (124/267) 47.5 (84/177) 44.4 (40/90) 0.698
a 5 participants specified the ‘other’ reason for presenting at the clinic, i.e. flu, headache/dizziness, chest pain, contraception and tonsillitis.
b Percentages add up to >100% because participants could choose more than one answer.
c Progesterone injections were either medroxyprogesterone acetate or norethisterone enantate injections.
d Etonogestrel Implanon or Nexplanon implants
https://doi.org/10.1371/journal.pone.0196209.t001
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required repeat doses of Metronidazole to clear the syndrome. One woman was HIV antibody
negative at enrolment, but tested positive at 6 weeks. No other HIV infections were detected
during the 12-week follow-up.
Focus group discussions
A total of 29 women participated in six focus group discussions to assess the acceptability and
feasibility of POC STI testing and EPT. Overall, women were relieved to receive a specific STI
diagnosis with immediate treatment, which none of them had experienced previously. A
Table 2. Prevalence of STIs, bacterial vaginosis and candidiasis at baseline in 267 young South African women.
Variable Overall
(N = 267)
% (95% Cl)
< 25 years
(N = 177)
% (95% CI)
>25 years
(N = 90)
% (95% CI)
p-value
C. trachomatis (CT) 18.4 (13.7–23.0) 20.3 (14.4–26.3) 14.6 (7.2–21.7) 0.315
N. gonorrhoeae (NG) 5.2 (2.6–7.9) 5.6 (2.2–9.1) 4.4 (0.2–8.7) 0.779
T. vaginalis (TV) 3.0 (1.0–5.0) 1.7 (0–3.6) 5.6 (0.8–10.3) 0.129
CT, NG or TV 23.6 (18.5–28.7) 24.3 (18.0–30.6) 22.2 (13.6–30.8) 0.762
Vaginal flora (Nugent score) 7–10 33.7 (28.0–39.4) 33.3 (26.4–40.3) 34.4 (24.6–44.3) 0.986
4–6 35.6 (29.8–41.3) 35.6 (28.5–42.6) 35.6 (25.7–45.4)
0–3 30.7 (25.2–36.2) 31.1 (24.3–37.9) 30.0 (20.5–39.5)
Candida 18.0 (13.4–22.6) 19.8 (13.9–25.6) 14.4 (7.2–21.7) 0.316
https://doi.org/10.1371/journal.pone.0196209.t002
Fig 1. Consort diagram of expedited partner therapy intervention for women in the CAPRISA 083 cohort study.
Consenting women were offered participation in the CAPRISA 083 study and underwent point-of-care (POC) testing
for sexually transmitted infections (STI). Those diagnosed with Chlamydia (CT), Gonorrhoea (NG) or Trichomoniasis
(TV) were offered expedited partner therapy (EPT) to deliver to their partners. Women were contacted by phone one
week later, and retested for STIs after six weeks. Some women were lost to follow-up (LTFU).
https://doi.org/10.1371/journal.pone.0196209.g001
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specific STI diagnosis meant that women could have a meaningful STI discussion with the
nursing staff. Women reported that the STI diagnosis and provision of EPT allowed them to
begin communicating with their partners about sexual relationships, and start to renegotiate
these, if required. Women reported several outcomes of these discussions including leaving
their partners, improved condom use, or continuing their relationships after partner treat-
ment. Overall, women reported that their male sexual partners found EPT helpful for practical
reasons, as they did not have to travel to clinics or take time off work to get treated. A few
women reported that men got upset about the STI diagnosis or were reluctant to take EPT, but
despite this, the majority of men eventually took the EPT. Importantly, women did not report
any instances of intimate partner violence as a result of EPT.
Discussion
This cohort study in young South African women found that an innovative combined model
of POC STI testing, immediate treatment, and EPT can be a useful way to reduce the STI bur-
den in LMICs. The study showed that POC STI testing is robust, can be delivered by a labora-
tory technologist and produces results within 2 hours, a timeframe acceptable to the women.
The majority of women accepted EPT and found the EPT pack a useful tool to treat and engage
their sexual partners in meaningful discussions about safer sex, condom use, and their rela-
tionships. In addition, women who successfully delivered EPT to their sexual partners had sta-
tistically lower STI prevalence at follow-up compared to those who did not.
The majority of research on POC STI testing implementation has been conducted in high
income countries, including the United States, United Kingdom, and Australia [26,27,28]. The
POC tests used in this study were the PCR-based Xpert1 CT/NG assay (approximate cost per
test USD 14.37) and the OSOM1 Rapid Trichomonas Test, an antigen detection assay (approx-
imate cost per test USD 8.00), both of which have been evaluated in multiple settings and
achieved high sensitivity and specificity [26,29,30]. Our study showed that these technologies
Table 3. Comparison of STI detection rates among 51 women with STIs, 6 weeks after an EPT intervention.
Pathogen Overall
(N = 51)
% (n/N)
EPT issued
(N = 46)
% (n/N)
No EPT issued
(N = 5)
% (n/N)
p-value
C. trachomatis 3.9 (2/51) 2.2 (1/46) 20.0 (1/5) 0.188
T. vaginalis 2.0 (1/51) 0 20.0 (1/5) 0.098
C. trachomatis or T. vaginalis a 5.9 (3/51) 2.2 (1/46) 40.0 (2/5) 0.023
a No N. gonorrhoeae cases were detected at 6-week follow-up
https://doi.org/10.1371/journal.pone.0196209.t003
Table 4. STI detection after POC STI testing, immediate treatment and EPT intervention.
Pathogen (N = 77) a Baseline N (%) Week 6 N (%) Week 12 N (%) p-value
C. trachomatis (CT) 35 (45.5) 4 (5.2) 2 (2.6) <0.001
N. gonorrhoeae (NG) 10 (13.0) 0 (0) 1 (1.3) 0.041
T. vaginalis (TV) 5 (6.5) 2 (2.6) 0 (0) 0.013
Any of CT, NG or TV 46 (59.7) 6 (7.8) 3 (3.9) <0.001
Bacterial vaginosis 40 (52.0) 26 (33.8) 19 (24.7) <0.001
Nugent Scores mean (IQR) 6.2 (5–7) 5.2 (3–8) 4.8 (3–6) <0.001
Candidiasis 14 (18.2) 7 (9.1) 12 (15.6) 0.668
a Women with STIs or BV were included if they attended all follow up visits.
https://doi.org/10.1371/journal.pone.0196209.t004
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can be used in a LMIC setting, which is encouraging for the development of a workable STI
care model, especially in South Africa and other LMICs where the GeneXpert platform has
been widely implemented for the rapid diagnosis of Tuberculosis. Additional benefits of this
technology include the recent availability of a TV cartridge [31]. In line with other POC molecu-
lar diagnostic tests, results currently take several hours to be available, prolonging clinic visit
times. Patients in our and other studies did not find this to be problematic, however speedier
assays would facilitate patient care and satisfaction [32,33,34].
Our study showed that EPT was acceptable to women, as evidenced by the high uptake, and
decreased STI infections at 6 weeks, compared to women who did not take EPT. This com-
parison was limited by the cohort design of the study and the very small sample of women not
taking up EPT. Several other studies have shown that EPT is acceptable to populations and
effective in increasing partner treatment and decreasing reinfection rates, but these have pri-
marily been conducted in high income countries [18,35]. However, some studies conducted
in LMICs found that EPT was effective in treating partners and acceptable to participants
[20,21,36]. In a study from Peru, when participants were offered the choice between concur-
rent patient partner treatment or EPT, 61.8% chose EPT [36]. Similarly, in a study of female
sex workers from Uganda 50.6% accepted EPT for their regular partners. Reported barriers
included stigma, fear of being viewed as the primary source of the STI, and loss of contact with
sexual partners [37]. Furthermore, similar to our study, research from a different region in
South Africa found that EPT was successful in alleviating partners’ fears of visiting or taking
time off work to attend a clinic [20].
As confirmed in our study, STIs are common in KwaZulu-Natal, which is also the epicentre
of the HIV epidemic, with nearly half of all new HIV infections occurring in 15–24 year-old
women [38,39]. The approach of POC testing and immediate treatment led to significant
decreases in all STIs at 12 weeks in participants. Treating STIs early and reducing reinfection
by treating the sexual partners is therefore particularly important for these young South Afri-
can women. At a personal level, not only will this improve the sexual and reproductive health
of women and their newborns, but it may also reduce their risk of acquiring HIV, by prevent-
ing breaches in the mucosal layer or an increase in HIV target cells in the genital tract [40,41].
At a population level, it may have a positive impact on the STI and HIV epidemics.
To the best of our knowledge, this is the first time a model of POC STI testing, immediate
treatment, EPT and test of cure has been evaluated in a LMIC setting. Depending on technol-
ogy innovations, regional epidemiology, and local resources and infrastructure, the individual
components of this model could be adapted. For example, given the low detection rates after
the intervention, the test of cure could be removed from the model, reducing costs and
complexity.
This proof-of-concept study has some limitations including the relatively small sample size,
the single urban site setting, and the lack of a cost-effectiveness evaluation. However, this was
offset by the fact that the study was conducted by a skilled multi-disciplinary team in a high
STI and HIV burden setting, and was able to assess a multi-method approach. While retention
rates and EPT uptake were high in the study, this needs to be replicated in a busy clinic setting
without dedicated research team support. Finally, some will argue that the feasibility of rolling
out EPT at a population level will depend on a more robust surveillance system to detect anti-
biotic resistance, particularly to NG, in LMICs. Others may argue that these systems should be
in place irrespective of the STI care model, and that EPT, by decreasing the overall STI burden,
could contribute to keeping antibiotic resistance contained.
Our study suggests that the model of POC STI testing, immediate therapy, EPT and test of
cure was acceptable to young South African women and their partners, and resulted in lower
STI detection rates on test of cure samples. Larger randomized controlled trials in LMICs
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should evaluate the feasibility and cost-effectiveness of implementing this strategy at popula-
tion level, and the effect on STI prevalence and HIV incidence.
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